Edwards Lifesciences Corp. said late Friday it will buy privately-held CardiAQ Valve Technologies Inc. for up to $400 million, including $350 million in cash at closing. The remainder will be paid after achieving a European regulatory milestone. The deal is expected to be dilutive to its 2015 earnings and Edwards will provide details when it releases second-quarter results on July 28. CardiAQ is a developer of a transcatheter mitral valve replacement system but its valve system is not approved for sale in any country, according to Edwards.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News